Cargando…

In search of the optimal proteosome inhibitor. How, when and for whom?

Detalles Bibliográficos
Autores principales:	Engelhardt, Monika, Bringhen, Sara, Moreau, Philippe, Wäsch, Ralph, Waldschmidt, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485685/ https://www.ncbi.nlm.nih.gov/pubmed/33910336 http://dx.doi.org/10.3324/haematol.2021.278838

Ejemplares similares

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Pediatric Percutaneous Endoscopic Gastrostomy in Korea - When? By Whom? How?
por: Lee, Yoon
Publicado: (2022)

Freeze-all, for whom, when, and how
por: Celada, Paula, et al.
Publicado: (2020)

Emergency airway management – by whom and how?
por: Sollid, S. J. M., et al.
Publicado: (2016)

Unguided De-Escalation Strategy From Potent P2Y(12) Inhibitors in Patients Presented With ACS: When, Whom and How?
por: Park, Jin Sup, et al.
Publicado: (2022)

Radiotherapy in Pancreatic Cancer: To Whom, When, and How?
por: Falco, Michał, et al.
Publicado: (2023)

Non-invasive ventilation in the ED: Whom, When, How?
por: Göksu, Erkan, et al.
Publicado: (2018)

Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How
por: Pavanello, Francesca, et al.
Publicado: (2016)

Defibrillation Testing of the Implantable Cardioverter Defibrillator: When, How, and by Whom?
por: Pires, Luis A
Publicado: (2007)

Prone position in ARDS patients: why, when, how and for whom
por: Guérin, Claude, et al.
Publicado: (2020)

Editorial: Personalized nutrition with polyphenols—which, for whom, when and how?
por: Weseler, Antje R., et al.
Publicado: (2023)

Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?
por: Jourde-Chiche, Noémie, et al.
Publicado: (2023)

Intradialytic parenteral nutrition for patients on hemodialysis: when, how and to whom?
por: Carrero, Juan J, et al.
Publicado: (2022)

Radiation resistance in breast cancer: are CD44(+)/CD24(-)/proteosome(low)/PKH26(+ )cells to blame?
por: Nakshatri, Harikrishna
Publicado: (2010)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Itraconazole in chronic pulmonary aspergillosis: In whom, for how long, and at what dose?
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2015)

Noninvasive respiratory support for COVID-19 patients: when, for whom, and how?
por: Sullivan, Zachary P., et al.
Publicado: (2022)

Electroconvulsive therapy following incident bipolar disorder: When, how, and for whom?
por: Salagre, Estela, et al.
Publicado: (2022)

The future … to whom it belongs?()
por: Abrahão, Marcio
Publicado: (2016)

To Whom It May Concern
Publicado: (1888)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy
por: Greil, Christine, et al.
Publicado: (2022)

Credit to Whom Credit Is Due
Publicado: (1871)

Credit to Whom Credit Is Due
Publicado: (1853)

Credit to Whom Credit Is Due
Publicado: (1855)

To Whom Belongs the Honor of Discovery?
Publicado: (1893)

Credit to Whom Credit Is Due
Publicado: (1888)

Credit to Whom Credit Is Due
Publicado: (1883)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019)

The when, why and whom to biopsy of type 1 diabetes mellitus children with positive anti-tissue transglutaminase serology
por: Guandalini, Stefano
Publicado: (2023)

Whom to further monitor in remote monitoring?
por: Barake, Walid, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
por: Wu, Jia-Feng
Publicado: (2022)

Oncoplastic Breast Surgery: What, When and for Whom?
por: Macmillan, R. Douglas, et al.
Publicado: (2016)

COVID-19 patients: when and whom to ventilate?
por: Lal, Tusharindra, et al.
Publicado: (2020)

Midwifery continuity of care: A scoping review of where, how, by whom and for whom?
por: Bradford, Billie F., et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lhtaqfg4n6vecga2hlduqjta0